Abstract 902P
Background
Cisplatin (CDDP) is the most frequently used chemotherapeutic agent for head and neck cancer (HNC). The objectives of this study were to estimate the incidence rate of CDDP-induced ototoxicity (CIO) and the threshold dose causing ototoxicity, and reveal the related factors in HNC.
Methods
Three hundred and thirty-two patients of HNC received chemotherapy containing CDDP at Kyoto University Hospital from June 2009 to December 2022. The distortion product otoacoustic emission (DPOAE), tympanometry (TPG), and pure-tone audiometry (PTA) were measured after each administration of CDDP. Patients with bilateral conductive hearing loss, and/or the ear side with otitis media were excluded. The factors associated with CIO synergistically were investigated by evaluating the baseline characteristics.
Results
A total of 304 of the 332 patients were included in the analysis. The mean age before CDDP administration was 60.5 years (range, 24-79). Primary sites were nasopharynx (6.6%), oropharynx (21.1%), hypopharynx (20.7%), larynx (7.2%), oral cavity (28.3%), paranasal sinuses (8.9%), and other sites (7.2%). The mean cumulative CDDP doses were 200.0 mg/m2 (range, 48- 800, median 190.0). Dose-dependent hearing threshold shift was observed mainly in the high-frequency speech range. The incidence rate of ototoxicity detected by DPOAE and PTA were 46.4% and 37.8%, respectively. The median cisplatin doses causing deterioration of DPOAE were lower than PTA (210.0 mg/m2 v.s.258.0 mg/m2, p < 0.05). Above 300 mg/m2 of cumulative CDDP dose, CIO was detected in 56.5% by PTA. Related factors for CIO were the cumulative doses of CDDP, concurrent use of radiotherapy, and high-frequency hearing impairment before treatment (p < 0.05, respectively).
Conclusions
Implicit hearing loss caused by CDDP was observed at dose of 211 mg/m2, although subjective hearing loss appeared at dose of 258 mg/m2. Cumulative doses of CDDP, concurrent use of radiotherapy, and high-frequency hearing impairment before treatment were identified as risk factors for CIO. Monitoring of hearing level is suggested for early detection of CIO especially in patients with high-frequency hearing impairment before treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
932P - Survival in patients with relapsed/metastatic head and neck squamous cell carcinoma (HNSCC) treated with pembrolizumab or cetuximab-based therapy: A real-worlddata study with the TriNetX platform
Presenter: Lisardo Ugidos De La Varga
Session: Poster session 12
934P - Antitumor activity and safety profile of camrelizumab plus docetaxel, cisplatin, and capecitabine for induction therapy in advanced stage hypopharyngeal carcinoma
Presenter: Hongli Gong
Session: Poster session 12
938P - Nivolumab (nivo) in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN): real-world effectiveness, quality of life (QoL) of patients and their caregivers in France (ProNiHN study)
Presenter: Christophe Le Tourneau
Session: Poster session 12
939P - Efficacy and safety of a novel anti-EGFR ADC MRG003 in recurrent or metastatic squamous cell carcinoma of the head and neck patients
Presenter: Liqiong Xue
Session: Poster session 12
940P - Salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck included in the phase II TOPNIVO trial
Presenter: Khalil Saleh
Session: Poster session 12
941P - Risk factors for progressive disease after immune checkpoint inhibitors (ICIs) in advanced head and neck squamous cell carcinoma (HNSCC): Who might not be candidate for ICI?
Presenter: Seo Yoon Jang
Session: Poster session 12